Anti-CTLA4/ CTLA-4/ ALPS5 monoclonal antibody

Anti-CTLA4/ CTLA-4/ ALPS5 antibody for FACS & in-vivo assay

Target products collectionGo to CTLA-4/CTLA4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T15000-Ab-1/ GM-Tg-hg-T15000-Ab-2Anti-Human CTLA-4/CTLA4 monoclonal antibodyHuman
GM-Tg-rg-T15000-Ab-1/ GM-Tg-rg-T15000-Ab-2Anti-Rat CTLA-4/CTLA4 monoclonal antibodyRat
GM-Tg-mg-T15000-Ab-1/ GM-Tg-mg-T15000-Ab-2Anti-Mouse CTLA-4/CTLA4 monoclonal antibodyMouse
GM-Tg-cynog-T15000-Ab-1/ GM-Tg-cynog-T15000-Ab-2Anti-Cynomolgus/ Rhesus macaque CTLA-4/CTLA4 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T15000-Ab-1/ GM-Tg-felg-T15000-Ab-2Anti-Feline CTLA-4/CTLA4 monoclonal antibodyFeline
GM-Tg-cang-T15000-Ab-1/ GM-Tg-cang-T15000-Ab-2Anti-Canine CTLA-4/CTLA4 monoclonal antibodyCanine
GM-Tg-bovg-T15000-Ab-1/ GM-Tg-bovg-T15000-Ab-2Anti-Bovine CTLA-4/CTLA4 monoclonal antibodyBovine
GM-Tg-equg-T15000-Ab-1/ GM-Tg-equg-T15000-Ab-2Anti-Equine CTLA-4/CTLA4 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T15000-Ab-1/ GM-Tg-hg-T15000-Ab-2; GM-Tg-rg-T15000-Ab-1/ GM-Tg-rg-T15000-Ab-2;
GM-Tg-mg-T15000-Ab-1/ GM-Tg-mg-T15000-Ab-2; GM-Tg-cynog-T15000-Ab-1/ GM-Tg-cynog-T15000-Ab-2;
GM-Tg-felg-T15000-Ab-1/ GM-Tg-felg-T15000-Ab-2; GM-Tg-cang-T15000-Ab-1/ GM-Tg-cang-T15000-Ab-2;
GM-Tg-bovg-T15000-Ab-1/ GM-Tg-bovg-T15000-Ab-2; GM-Tg-equg-T15000-Ab-1/ GM-Tg-equg-T15000-Ab-2
Products NameAnti-CTLA-4/CTLA4 monoclonal antibody
Formatmab
Target NameCTLA-4
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CTLA-4 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-088Pre-Made Cadonilimab biosimilar, Bispecific Mixed mAb and scFv, Anti-PDCD1/PD-1;CTLA4/CTLA-4 antibody: Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
    BiosimilarGMP-Bios-ab-679Pre-Made Lorigerlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1;CTLA4/CTLA-4 Antibody: Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
    BiosimilarGMP-Bios-ab-460Pre-Made Quavonlimab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
    BiosimilarGMP-Bios-ab-382Pre-Made Nurulimab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
    BiosimilarGMP-Bios-ab-078Pre-Made Botensilimab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
    BiosimilarGMP-Bios-ab-704Pre-Made Tuvonralimab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
    BiosimilarGMP-Bios-INN-712Pre-Made Abatacept Biosimilar, Fusion Protein targeting CTLA4/CTLA-4 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3
    BiosimilarGMP-Bios-ab-631Pre-Made Vudalimab biosimilar, Bispecific Mixed mAb and scFv, Anti-CTLA4/CTLA-4;PDCD1/PD-1 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3;CD279/SLEB2/hPD-1/hPD-l/hSLE1 therapeutic antibody
    BiosimilarGMP-Bios-ab-277Pre-Made Ipilimumab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
    BiosimilarGMP-Bios-ab-194Pre-Made Erfonrilimab biosimilar, Bispecific Single Domains (VH-VH'-CH), Anti-CD274/PD-L1;CTLA4/CTLA-4 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
    BiosimilarGMP-Bios-ab-569Pre-Made Ticilimumab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
    BiosimilarGMP-Bios-ab-636Pre-Made Zalifrelimab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
    BiosimilarGMP-Bios-ab-432Pre-Made Pavunalimab biosimilar, Bispecific Mixed mAb and scFv, Anti-LAG3;CTLA4/CTLA-4 Antibody: Anti-CD223;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
    BiosimilarGMP-Bios-ab-595Pre-Made Tremelimumab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
    Target AntigenProducts DevelopingMulti-species CTLA4/ CTLA-4/ ALPS5 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorpGMLP004479human CTLA4 Lentivirus plasmid
    ORF Viral VectorvGMLP004479human CTLA4 Lentivirus particle
    ORF Viral VectorpGMLPm000482mouse Ctla4 Lentivirus plasmid
    ORF Viral VectorvGMLPm000482mouse Ctla4 Lentivirus particle


    Target information

    Target IDGM-T15000
    Target NameCTLA-4
    Gene ID1493,12477,63835,705673,403696,493743,281732,100067931
    Gene Symbol and SynonymsALPS5,CD,CD152,CELIAC3,CTLA-4,CTLA4,GRD4,GSE,IDDM12,Ly-56,sCTLA4
    Uniprot AccessionP16410,Q9XSI1
    Uniprot Entry NameCTLA4_HUMAN,CTLA4_CANLF
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index
    DiseaseHepatitis - type 1 autoimmune, Grave's Disease, Autoimmune thyroid diseases, asthma
    Gene EnsemblENSG00000163599
    Target ClassificationCheckpoint-Immuno Oncology

    The target: CTLA-4, gene name: CTLA4, also named as ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12. This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.